The estimated Net Worth of Cooper C. Collins is at least $9.51 million dollars as of 22 August 2024. Mr. Collins owns over 4,094 units of TherapeuticsMD Inc stock worth over $92,479 and over the last 13 years he sold TXMD stock worth over $9,210,527. In addition, he makes $202,508 as Independent Director at TherapeuticsMD Inc.
Sign up
Mr. Collins TXMD stock SEC Form 4 insiders trading
Cooper has made over 15 trades of the TherapeuticsMD Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 4,094 units of TXMD stock worth $7,083 on 22 August 2024.
The largest trade he's ever made was selling 2,631,579 units of TherapeuticsMD Inc stock on 14 June 2013 worth over $4,605,263. On average, Cooper trades about 199,297 units every 108 days since 2012. As of 22 August 2024 he still owns at least 52,016 units of TherapeuticsMD Inc stock.
You can see the complete history of Mr. Collins stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Cooper Collins biography
Cooper C. Collins serves as Independent Director of the Company. Mr. Collins has served as Chief Executive Officer of Fortis BioPharma LLC since June 2015. Mr. Collins served as Chief Strategy Officer of Pernix Therapeutics Holdings, Inc. [NASDAQ: PTX], or Pernix, from May 2013 until April 2014, as its President and Chief Executive Officer from March 2010 until May 2013, and as a director from March 2010 until February 2014. Mr. Collins joined Pernix Therapeutics, Inc., a predecessor of Pernix, in 2002, where he was appointed as a director in January 2007, its President in December 2007 and its Chief Executive Officer in June 2008, serving in those three capacities until March 2010. From December 2005 to December 2007, Mr. Collins served as Vice President of Business and Product Development of Pernix Therapeutics, Inc. and as its Territory Manager from December 2003 to December 2005. Mr. Collins was employed for three years by the National Football League franchise, the New Orleans Saints, in its media relations department. While on a football scholarship, Mr. Collins received a B.A. from Nicholls State University, where he later received an M.B.A.
What is the salary of Cooper Collins?
As the Independent Director of TherapeuticsMD Inc, the total compensation of Cooper Collins at TherapeuticsMD Inc is $202,508. There are 8 executives at TherapeuticsMD Inc getting paid more, with John Milligan having the highest compensation of $1,440,640.
How old is Cooper Collins?
Cooper Collins is 41, he's been the Independent Director of TherapeuticsMD Inc since 2012. There are 25 older and 1 younger executives at TherapeuticsMD Inc. The oldest executive at TherapeuticsMD Inc is Tommy Thompson, 78, who is the Independent Chairman of the Board.
What's Cooper Collins's mailing address?
Cooper's mailing address filed with the SEC is 951 YAMATO ROAD, SUITE 220, BOCA RATON, FL, 33431.
Insiders trading at TherapeuticsMD Inc
Over the last 13 years, insiders at TherapeuticsMD Inc have traded over $21,656,853 worth of TherapeuticsMD Inc stock and bought 721,732 units worth $2,299,099 . The most active insiders traders include Cooper C. Collins, Brian Bernick et Robert G Finizio. On average, TherapeuticsMD Inc executives and independent directors trade stock every 29 days with the average trade being worth of $272,607. The most recent stock trade was executed by John C.K. Iv Milligan on 25 October 2019, trading 72,000 units of TXMD stock currently worth $198,000.
What does TherapeuticsMD Inc do?
therapeuticsmd, inc. is an innovative pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their health care issues. we create products to address the unique changes and challenges women experience through every stage of their lives. with momentum fueled by the needs of our customers, we combine entrepreneurial spirit and clinical expertise to develop innovative solutions designed to go beyond what is presently available. this includes a variety of therapies in our pipeline, along with prescription prenatal vitamins under the vitamedmd® and bocagreenmd® brands. see our community guidelines: https://www.therapeuticsmd.com/social-media-community-guidelines
What does TherapeuticsMD Inc's logo look like?
Complete history of Mr. Collins stock trades at TherapeuticsMD et TherapeuticsMD Inc
TherapeuticsMD Inc executives and stock owners
TherapeuticsMD Inc executives and other stock owners filed with the SEC include:
-
John Milligan,
President, Secretary -
Brian Bernick,
Co-Founder -
Robert Finizio,
Chief Executive Officer and Director -
Robert G. Finizio,
Co-Founder & Vice Chair -
Mitchell Krassan,
Chief Strategy and Performance Officer -
John C. K. Milligan IV,
Chief Exec. Officer of VitaCare Prescription Services -
Michael Donegan,
Vice President - Finance -
Tommy Thompson,
Independent Chairman of the Board -
Cooper Collins,
Independent Director -
J. Martin Carroll,
Independent Director -
Angus Russell,
Independent Director -
Jules Musing,
Independent Director -
Dr. Brian A. Bernick,
Co-Founder & Chief Scientific Officer -
Nichol Ochsner,
Vice President, Investor Relations -
Gail Naughton,
Independent Director -
Karen Ling,
Independent Director -
Paul Bisaro,
Independent Director -
Bharat Warrier,
Chief Manufacturing Officer -
Sebastian Mirkin,
Chief Medical Officer -
Dawn Halkuff,
Chief Commercial Officer -
Marlan Walker,
General Counsel -
John Knighton,
Chief Compliance Officer -
Adam Miller,
Chief Information Officer -
James D'Arecca,
Chief Financial Officer -
Julia M. Amadio,
Chief Product Officer -
Mitchell L. Krassan,
Exec. VP and Chief Strategy & Performance Officer -
Chris Gish,
Sr. VP of Sales -
Michael Donegan,
Chief Accounting Officer & VP of Fin. -
James C. D'Arecca,
Chief Financial Officer -
Hugh O'Dowd M.B.A.,
Pres, CEO & Director -
Robert V Jr La Penta,
Director -
Nicholas Segal,
Director -
Jane F Barlow,
Director -
Daniel A Cartwright,
Chief Financial Officer -
Randall S Stanicky,
Director -
Samuel A Greco,
Director